Financial PerformanceNet income was $24.9M, or $0.03 per diluted share, beating our estimated loss of $66.5M due to $121.5M of gain on sale of assets.
Immuno-oncology AdvancementsModeX is developing tetraspecific LASER antibodies for immuno-oncology, with a Phase 1 trial in progress aiming to target solid tumors.
Vaccine DevelopmentMDX2201 has the potential to become the first EBV vaccine cleared for marketing in the U.S., addressing a virus with no current FDA-approved vaccine or treatment.